A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes

NCT06938334 | Not Yet Recruiting Phase 1 DMC

• 2 other identifiers: IMMUNOSTEM2025-521304-21-00
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Purpose: The purpose of the trial is to assess the safety profile of the study treatment and to evaluate its efficacy in terms of improvement in key diabetes management parameters, including insulin requirements and β-cell function, and immunological parameters, in patients with T1D at recent onset / diagnosis and with residual β-cell function. Rationale: The study treatment consists of an autologous CD34+-enriched population that contains HSPCs transduced ex vivo with a third generation VSV-G pseudotyped LVV encoding the hPD-L1 cDNA. The drug product (DP) is composed of genetically modified autologous CD34+ HSPCs formulated in cryopreservation medium, transferred to the final container closure, and cryopreserved. The mechanism of action is based on the ability of the PD-L1-expressing HSPCs to exert immunoregulatory properties activity and ablate suppress the autoimmune reaction induced by auto-reactive T lymphocytes, by homing to the site of inflammation, i.e., the pancreas. PD-L1 is the ligand for the PD-1 receptor, expressed primarily on activated T cells. Crosslinking of PD-L1 and PD-1 inhibits T cell activation and favours their exhaustion/apoptosis and in mice deficient in PD-L1/PD-1 develop accelerated diabetes. HSPCs have been extensively used as an effective therapeutic approach in haematological malignancies and have demonstrated to be safe in human subjects. Immunologically based clinical trials performed thus far have failed to cure T1D, in part because these approaches were nonspecific. Because the disease is driven by autoreactive CD4+ T cells, which destroy β cells, transplantation of hematopoietic stem and progenitor cells (HSPCs) has been recently offered as a therapy for T1D. Our transcriptomic profiling of HSPCs revealed that these cells are deficient in PD-L1, an important immune checkpoint, in the T1D non-obese diabetic (NOD) mouse model. Notably, the immunoregulatory molecule PD-L1 plays a determinant role in controlling/inhibiting activated T cells and thus maintains immune tolerance. Furthermore, our genome-wide and bioinformatic analysis revealed the existence of a network of microRNAs (miRNAs) controlling PD-L1 expression, and silencing one of key altered miRNAs restored PD-L1 expression in HSPCs. The Investigators therefore sought to determine whether restoration of this defect would cure T1D as an alternative to immunosuppression. Genetically engineered or pharmacologically modulated HSPCs overexpressing PD-L1 inhibited the autoimmune response in vitro, reverted diabetes in newly hyperglycemic NOD mice in vivo, and homed to the pancreas of hyperglycemic NOD mice. The PD-L1 expression defect was confirmed in human HSPCs in T1D patients as well, and pharmacologically modulated human HSPCs also inhibited the autoimmune response in vitro. The Investigators therefore hypothesized that targeting a specific immune checkpoint defect in HSPCs thus may contribute to establishing a cure for T1D or slow the progression of β-cell destruction.

Conditions

Diabetes, Type I

Keywords

type 1 diabetes (T1D); HSPCs genetically modified; lentiviral vector (LVV)

Outcome Measures

Primary Outcomes (1)

• Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0

  For each participant, number, description and grading of any adverse event, including expected and unexpected adverse events, meeting or not meeting the definition of "serious".

  Up to 24 months

Secondary Outcomes (7)

• Vector Copy Number

  Up to 24 months

• Safety and efficacy

  on month 12 and 24 month

• Safety and efficacy

  on month 12 and 24 month

• Safety and efficacy

  Up to 24 months

• Pharmacodynamic

  from Treatment to end of study

Study Arms (1)

Treatment

EXPERIMENTAL

Evaluation of the safety and efficacy of autologous CD34+ HSPCs transduced ex vivo with LVV encoding hPD-L1 cDNA in patients with T1D at recent onset and with residual β-cell function

Genetic: Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA

Interventions

Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA GENETIC

The intervention is intended for newly diagnosed T1D patients with residual beta-cell function, who can receive the Drug Product (DP) within 180 days from the first insulin administration. Mobilized autologous HSPCs, collected by leukapheresis, are ex vivo transduced with a LVV encoding for hPD-L1 and formulated in a cryopreservation medium containing DMSO (DP). After release, the DP is thawed and administered to the patient at a dose ranging between 5 and 20 million of cells per kilogram of body weight. The intervention plans for a single DP injection.

Treatment

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Capable of giving signed informed consent, compliance with the requirements and restrictions listed in the Informed Consent Form and the protocol.
• Male and or female patients.
• Age ≥18 and ≤40 years
• Patient able to comply with all protocol procedures for the duration of the study.
• Recent T1D onset/diagnosis (patients should receive the DP within 180 days from the 1st insulin administration).
• HbA1c ≥53 and ≤150 mmol/mol
• Positivity to at least 2 autoantibodies (i.e., anti-insulin, IAA; anti-glutamic acid decarboxylase 65, GAD65; anti-islet antigen 2, IA-2A; anti-zinc transporter 8, ZnT8; anti-islet cell antibody, ICA).
• Basal C-peptide levels ≥0.2 nmol/L or ≥0.6 ng/mL; if basal C-peptide levels \<0.2 nmol/L, stimulated C-peptide peak ≥0.2 nmol/L or ≥0.6 ng/mL during a 2-hour MMTT; MMTT should not be performed within one week of resolution of a diabetic ketoacidosis event.

You may not qualify if:

• Unwillingness to sign the informed consent.
• Type 2 diabetes
• Any other unstable chronic disease
• Significant systemic infection during the four weeks before requiring hospitalisation, administration of intravenous antibiotics, surgery
• Present administration of chemotherapeutic anti-neoplastic drugs.
• QTcF \>470 msec.
• Occurrence of an episode of ketoacidosis or hypoglycaemic coma in the past two weeks.
• Presence of a ≥grade 3 adverse event (including laboratory analyses) according to CTCAE version 5.0.
• Evidence of clinically significant abnormalities at bone-marrow aspirate
• Body Mass Index (body weight\*height2 )\>27 kg⁄m2
• A positive result to Biological Screening testing for Anti-HCV Antibody (Ab), HCV nucleic acid test (NAT) (if anti-HCV Ab positive), HIV-1/-2 p24 Ab and antigen (Ag), HIV RNA NAT, anti-Treponema pallidum total Ig, HbsAg (Australia Ag), HBV DNA NAT, total anti-HB core Ab (if HBV DNA NAT positive), anti-HTLV I, and anti-HTLV II (if applicable).
• Active SARS-CoV-2 infection.
• Allergy to mobilizing agents (G-CSF and plerixafor).
• Pregnancy or lactation
• Absence of an efficacious method of contraception

Sponsors & Collaborators

• Altheia Science: lead
• Evidenze Health S.r.l.: collaborator

Study Sites (1)

Azienda Ospedale-Università Padova

Padua, Italia, Italy

Location

Related Publications (1)

• Ben Nasr M, Tezza S, D'Addio F, Mameli C, Usuelli V, Maestroni A, Corradi D, Belletti S, Albarello L, Becchi G, Fadini GP, Schuetz C, Markmann J, Wasserfall C, Zon L, Zuccotti GV, Fiorina P. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Transl Med. 2017 Nov 15;9(416):eaam7543. doi: 10.1126/scitranslmed.aam7543.

  PMID: 29141886 BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Paolo Rizzardi, MD

CONTACT

+39 335 1935042; paolo.rizzardi@altheiascience.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 7, 2025
• First Posted: April 22, 2025
• Study Start: August 15, 2025
• Primary Completion (Estimated): June 15, 2029
• Study Completion (Estimated): June 15, 2029
• Last Updated: April 22, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: June 2029 - June 2030

Locations

IT (1)